Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 22, Art. 48 (pp. 677-688)    |    2021       

»

Treatment of bacterial vaginosis associated with an asymptomatic form of papillomavirus infection

Shperling N.V., Shperling I.A.

Federal State Budgetary Establishment «State Scientific Research Test Institute of the military medicine of the Russian Federation Defense Ministry»

Brief summary

Purpose of research. To present the experience of using vaginal cream with clindamycin and butoconazole in the treatment of bacterial vaginosis associated with an asymptomatic form of papillomavirus infection. Material and methods. 60 women aged 23 to 49 years (average age - 32+-5 years) with a diagnosis of Bacterial vaginosis were examined on a voluntary basis. Papillomavirus infection of the urogenital tract, asymptomatic form". The recurrence rate of bacterial vaginosis was 4-6 times a year. The microscopic picture of the vaginal biotope corresponded to vaginal dysbiosis. Criteria for exclusion from the study: intraepithelial lesions and malignant processes (based on the results of cytological examination of a cervical smear for oncocytology); concomitant sexually transmitted infections (Mycoplasma genitalium, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis). All patients were prescribed treatment according to the original prolonged scheme: vaginal cream with clindamycin and butoconazole (Clindacin B prolong) 1 time a day, in a single dose for 6 days daily, then-1 time a week in a single dose for 6 weeks. Results. The use of Clindacin B prolong cream after 3 months stopped the clinical manifestations and vaginal dysbiosis. 6 months after the start of treatment, 44 patients (73.3%) were found to have eliminated the human papillomavirus from the urogenital tract; in other cases, the viral load decreased. This is due to the immune-mediated reaction of the body in the conditions of normalization of the vaginal microbiome, which ensures the restoration of barrier function and local immunity. Conclusion. In women with bacterial vaginosis, associated with the asymptomatic form of human papillomavirus infection, use of vaginal cream with clindamycin and prolonged butokonazola for the scheme without additional use of immunomodulators offers long-lasting remission of bacterial vaginosis by a decrease in load of human papillomavirus in tissues uropetala tract, absence of clinical manifestation of human papillomavirus infection.


Key words

bacterial vaginosis, papillomavirus infection, Clindacin B prolong, clindamycin, butoconazole.

Reference list

1. Klinicheskie rekomendacii po diagnostike i lecheniu zabolevanii, soprovojdaushihsya patologicheskimi videleniyami iz polovih pytei jenshin. (Izdanie 2-e, ispravlennoe i dopolnennoe). Rossiiskoe obshestvo akysherov-ginekologov. M.; 2019. 56 c. [Clinical recommendations for the diagnosis and treatment of diseases accompanied by abnormal discharge from the genital tract of women. (2nd edition, revised and expanded). Russian society of obstetricians and gynecologists. Moscow; 2019. 56 p. (in Russian)].


2. Rodriguez-Cerdeira C., Sanchez-Blanco E., Alba A. Evaluation of association between vaginal infections and high-risk human papillomavirus types in female sex workers in Spain. ISRN Obstet. Gynecol. 2012. https://www.hindawi.com/journals/isrn/2012/240190/


3. Rogovskaya S.I., Lipova E.V. Sheika matki, vlagalishe, vylva. Rykovodstvo dlya praktikyushih vrachei. Izdanie 2. Status Preasens; 2016. 130 s. [Rogovskaya S.I., Lipova E.V. Cervix, vagina, vulva. A guide for medical practitioners. Edition 2. Status Praesens; 2016. 130 p. (in Russian)].


4. Kajina M.V., Yagovdik I.N., Gytikova L.V., Makarov S.N., Rapeckaya V.I., Svistynovich L.M. Papillomavirysnaya infekciya: izvestnoe o neizvestnom. Medicus. 2017; 14 (2): 8-14. [Kozhina M.V., Yagovdik I.N., Gutikova L.V., Makarov S.N., Rapetskaya V.I., Svistunovich L.M. Papillomavirus infection: known about unknown. Medicus. 2017; 14 (2): 8-14. (in Russian)].


5. Frazer I.H. The role of the immune system in anogenital human papillomavirus. Australas J. Dermatol. 1998; 39(1): 5-7.


6. Shperling N.V., Vengerovskii A.I., Zyev A.V., Chykaeva L.M., Shperling I.A. Osobennosti primeneniya indyktorov interferona y bolnih ostrokonechnim kondilomatozom anogenitalnoi oblasti. Kazanskii medicinskii jyrnal. 2008; 89(6): 811-814. [Shperling N.V., Vengerovsky A.I., Zuev A.V., Chukaeva L.M., Shperling I.A. Features of the use of interferon inducers in patients with acute condylomatosis of the anogenital region. Kazan medical journal. 2008; 89(6): 811-814. (in Russian)].


7. Shperling N.V. Vliyanie indyktorov interferona na citokinovii statys bolnih papillomavirysnoi infekciei genitalii, vizvannoi virysom papillomi cheloveka 6-go ili 11-go tipov. Bulleten sibirskoi medicini. 2009; 8(1): 56-60. [Sperling N.V. Influence of interferon inducers on the cytokine status of patients with papillomavirus infection of the genitals caused by human papillomavirus types 6 or 11. Bulletin of Siberian medicine. 2009; 8(1): 56-60. (in Russian)].





8. Prilepskaya V.N., Nazarova N.M. Papillomavirysnaya infekciya i bakterialnii vaginoz: est li vzaimosvyaz? Ginekologiya. 2014;16(4) : 4-6. [Prilepskaya V. N., Nazarova N.M. Papillomavirus infection and bacterial vaginosis: is there a relationship? Gynecology. 2014; 16(4): 4-6. (in Russian)].


9. Mitra A., Maclntyre D.A., Lee Y.S., Smith A., Marchesi J.R., Lehne B., Bhatia R., Lyons D., Paraskevaidis E., Li J.V., Holmes E., Nicholson J. K., Bennett P.R., Kyrgiou M. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci. Rep. 2015; 5: 1-11.


10. Ozgu E., Yilmaz N., Baser E., Gungor T., Erkaya S., Yakut H.I. Could 25-OH vitamin D deficiency be a reason for HPV infection persistence in cervical premalignant lesions? J Exp Ther Oncol. 2016; 11(3): 177-180.


11. Shperling N.V., Vengerovskii A.I., Shperling I.A. Optimizaciya sistemnoi terapii bolnih s bakterialnim vaginozom. Rossiiskii vestnik akyshera-ginekologa. 2014; 14(6): 103-107. [Shperling N.V., Vengerovsky A.I., Shperling I.A. Optimization of systemic therapy of patients with bacterial vaginosis. Russian Bulletin of obstetrician-gynecologist. 2014; 14(6): 103-107. (in Russian)].


12. Shperling N.V. Etiopatogeneticheskaya terapiya papillomavirysnoi infekcii, associirovannoi s bakterialnim vaginozom. Lechashii vrach. 2017; (4): 6-8. [Shperling N.V. Etiopathogenetic therapy of papillomavirus infection associated with bacterial vaginosis. Attending physician. 2017; (4): 6-8. (in Russian)].


13. Kravchenko E.N., Kyklina L.V., Cigankova O.U. Papillomavirysnaya infekciya i bakterialnii vaginoz: immynomodyliryushaya terapiya y beremennih. Mat i ditya v Kyzbasse. 2018; 72(2): 14-18. [Kravchenko E.N., Kuklina L.V., Tsygankova O.Yu. Papillomavirus infection and bacterial vaginosis: immunomodulatory therapy in pregnant women. Mother and child in Kuzbass. 2018; 72(2): 14-18. (in Russian)].


14. Shperling N.V., Romanova E.V., Shperling I.A. Mestnaya terapiya vaginitov v postmenopayze. Farmateka. 2018; 359(6): 48-54. [Shperling N.V., Romanova E.V., Shperling I.A. Local therapy of vaginitis in postmenopause. Farmateka. 2018; 359(6): 48-54. (in Russian)].


15. McClelland R.S., Balkus J.E., Lee J., Anzala O., Kimani J., Schwebke J., Bragg V., Lensing S., Kavak L. Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women. J Infect Dis. 2015; 211(12): 1875-1882.


16. Yankovskii D.S., Shirobokov V.P., Antipkin U.G., T.F. Tatarchyk, G.S. Diment. Mikrobiom i zdorove jenshini. Reprodyktivnaya endokrinologiya. 2015; 24(4): 13-28. [Yankovsky D.S., Shirobokov V.P., Antipkin Yu.G., T.F. Tatarchuk, H.S. Dyment. Microbiome and women's health. Reproductive endocrinology. 2015; 24(4): 13-28. (in Russian)].


17. Mirmonsef P., Gilbert D., Veazey R.S., Wang J., Kendrick S.R., Spear G.T. A comparison of lower genital tract glycogen and lactic acid levels in women and macaques: Implications for HIV and SIV susceptibility. AIDS Res Hum Retroviruses, 28(2012): 76-81.